Related Experiment Video
Updated: Feb 17, 2026
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.7K
[Acute severe ulcerative colitis treated with accelerated infliximab induction. Case report]
Daniela Fluxá, Lilian Flores1, Udo Kronberg1
1Clínica Las Condes, Santiago, Chile.
Revista Medica De Chile
|December 1, 2017
Summary
Accelerated infliximab induction therapy shows promise for acute severe ulcerative colitis (ASUC). This approach may improve treatment efficacy and reduce colectomy rates in patients with severe UC refractory to standard care.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Acute severe ulcerative colitis (ASUC) is a critical condition requiring prompt and effective treatment.
- Infliximab is recommended for corticosteroid-refractory ulcerative colitis (UC) after excluding infections.
- Standard weight-based infliximab dosing may be inadequate for ASUC patients.
Observation:
- A 34-year-old female with ASUC showed poor response to hydrocortisone and mesalazine.
- She received an accelerated infliximab induction regimen (10 mg/kg at weeks 0, 1, and 4).
Findings:
- The patient experienced significant symptom improvement after the second infliximab dose.
- Clinical remission was achieved and maintained for one year with subsequent maintenance therapy.
Implications:
- Accelerated infliximab induction may enhance serum concentrations and therapeutic efficacy in ASUC.
- This regimen could potentially decrease the need for early colectomy in severe UC cases.
- Further research into accelerated infliximab dosing for ASUC is warranted.
